Impairment of collateral formation in lipoprotein(a) transgenic mice: Therapeutic angiogenesis induced by human hepatocyte growth factor gene

Circulation

Volumn 105, Issue 12, 2002, Pages 1491-1496

  Morishita, Ryuichi ^a   Sakaki, Minako ^a   Yamamoto, Kei ^a   Iguchi, Sota ^a   Aoki, Motokuni ^a   Yamasaki, Keita ^a   Matsumoto, Kunio ^a   Nakamura, Toshikazu ^a   Lawn, Richard ^a   Ogihara, Toshio ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Angiogenesis; Arteries; Gene therapy; Growth substances; Lipoproteins

Indexed keywords

LIPOPROTEIN A; MITOGEN ACTIVATED PROTEIN KINASE; PLASMID VECTOR; SCATTER FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; BLOOD FLOW; CAPILLARY DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA; LIPOPROTEIN SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD FLOW VELOCITY; CELL DIVISION; CELLS, CULTURED; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; FEMALE; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; HINDLIMB; HUMANS; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; LIPOPROTEIN(A); MALE; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; PHOSPHORYLATION; PLASMIDS; SEX FACTORS;

EID: 0037177188     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000012146.07240.FD     Document Type: Article

References (34)

1. Second European consensus document on chronic critical leg ischemia
2. Fate of the patient with chronic leg ischaemia: A review article
3. Suggested standards for reports dealing with lower extremity ischemia: Ad Ho0c Committee on Reporting Standards: Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery
4. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease
5. Lipoprotein(a) and asymptomatic carotid artery disease: Evidence of a prominent role in the evolution of advanced carotid plaques: The Bruneck Study
6. Lipoprotein(a) levels and risk of coronary heart disease in men: The lipid Research Clinics Coronary Primary Prevention Trial
7. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis
8. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a)
9. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: A prospective study
10. Lipoprotein (a): A unique risk factor for atherothrombotic disease
11. Proliferation of human smooth muscle cells promoted by lipoprotein (a)
12. Conditioned medium from HepG2 cells transfected with human apolipoprotein (a) gene stimulates growth of human vascular smooth muscle cells: Effects of overexpression of human apolipoprotein (a) gene
13. Novel therapeutic strategy for atherosclerosis: Ribozyme oligonucleotides against apolipoprotein (a) selectively inhibit apolipoprotein (a), but not plasminogen, gene expression
14. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice
15. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
16. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta
17. Constitutive expression of ph VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
18. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results
19. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of ph VEGF165 as sole therapy for myocardial ischemia
20. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
21. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as "cytokine supplement therapy"
22. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis
23. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Down-regulation of HGF in response to hypoxia in vascular cells
24. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hind limb ischemia models: Preclinical study for treatment of peripheral arterial disease
25. Molecular cloning and expression of human hepatocyte growth factor
26. Atherogenesis in transgenic mice expressing human apolipoprotein (a)
27. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a)
28. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice
29. Rapid and sensitive enzymelinked immunosorbent assay for measurement of HGF in rat and human tissues
30. Phosphorylation of p38 MAP kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells
31. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients
32. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation
33. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis
34. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART)